Black Diamond, Inc., through its ownership of Black Diamond Equipment, Ltd., is engaged in designing, manufacturing and marketing of active outdoor performance equipment and apparel for climbing, mountaineering, backpacking, skiing and a range of other year-round outdoor recreation activities. The company has market cap of $159.10 million. The Company’s principal brands include Black Diamond and PIEPS. It currently has negative earnings. It offer a range of products, including apparel, such as jackets, shells, pants and bibs; rock-climbing equipment, such as carabiners, protection devices, harnesses, belay devices, helmets, and ice-climbing gear; technical backpacks and high-end day packs; tents; trekking poles; headlamps and lanterns, and gloves and mittens.
Among 24 analysts covering Teva Pharma (NYSE:TEVA), 12 have Buy rating, 0 Sell and 12 Hold. Therefore 50% are positive. Teva Pharma has $86 highest and $27 lowest target. $60’s average target is 85.70% above currents $32.31 stock price. Teva Pharma had 54 analyst reports since July 21, 2015 according to SRatingsIntel. The firm has “Buy” rating by Citigroup given on Tuesday, July 28. The firm has “Outperform” rating given on Thursday, March 30 by Maxim Group. OTR Global initiated the stock with “Positive” rating in Thursday, September 29 report. As per Friday, November 4, the company rating was downgraded by HSBC. The firm earned “Buy” rating on Monday, November 23 by Goldman Sachs. RBC Capital Markets maintained Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) rating on Wednesday, November 16. RBC Capital Markets has “Outperform” rating and $51 target. The rating was maintained by Mizuho on Tuesday, May 10 with “Buy”. The firm earned “Neutral” rating on Friday, July 15 by Goldman Sachs. Mizuho downgraded it to “Neutral” rating and $27 target in Friday, February 10 report. Mizuho maintained the stock with “Neutral” rating in Wednesday, November 16 report.
Ratings analysis reveals 17% of Black Diamond’s analysts are positive. Out of 6 Wall Street analysts rating Black Diamond, 1 give it “Buy”, 2 “Sell” rating, while 3 recommend “Hold”. The lowest target is $5 while the high is $7. The stock’s average target of $6 is 12.15% above today’s ($5.35) share price. BDE was included in 7 notes of analysts from September 11, 2015. The firm has “Underperform” rating by IBC given on Friday, September 11. As per Tuesday, March 7, the company rating was downgraded by Stifel Nicolaus. On Wednesday, March 30 the stock rating was downgraded by DA Davidson to “Neutral”. On Monday, March 21 the stock rating was maintained by Roth Capital with “Neutral”. The rating was downgraded by CBIC to “Underperform” on Friday, September 11. Canaccord Genuity maintained Black Diamond Inc (NASDAQ:BDE) rating on Monday, November 16. Canaccord Genuity has “Buy” rating and $6 target.
Wynnefield Capital Inc holds 2.25% of its portfolio in Black Diamond Inc for 1.17 million shares. Adirondack Research & Management Inc. owns 1.11 million shares or 2.01% of their US portfolio. Moreover, Lyon Street Capital Llc has 0.41% invested in the company for 149,326 shares. The Missouri-based Smith Moore & Co. has invested 0.27% in the stock. Eam Investors Llc, a California-based fund reported 267,410 shares.
Analysts await Black Diamond Inc (NASDAQ:BDE) to report earnings on May, 1.
The stock decreased 0.93% or $0.05 on April 7, reaching $5.35. About shares traded. Black Diamond Inc (NASDAQ:BDE) has risen 15.05% since September 1, 2016 and is uptrending. It has outperformed by 6.55% the S&P500.
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The company has market cap of $32.38 billion. The Firm is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. It has a 208.56 P/E ratio. The Firm operates through two divisions: Generic medicines and Specialty medicines.
